



VIA HAND DELIVERY JANUARY 21<sup>ST</sup>, 2003

Docket No.: PF348C1  
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Duan et al.

Application No.: 10/020,139

Group Art Unit: 1644

Filed: December 18, 2001

Examiner: M. Belyavskyi

For: Polynucleotides Encoding Human Parotid  
Secretory Protein (As Amended)

RECEIVED  
JAN 23 2003  
TECH CENTER 1600/2900

SUPPLEMENTARY INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. § 1.56

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to reference AN listed on the attached form PTO/SB/08.

Applicants also wish to bring to the attention of the Examiner that SEQ ID NO:1 and the corresponding cDNA clone of this application are related to SEQ ID NOs:43461, 43462, 43463, 43464, 45190 and 45231 in copending U.S. Patent Application Serial No. 09/912,292. A legible copy of those portions of U.S. Patent Application Serial No. 09/912,292, which caused it to be listed on the attached revised form PTO/SB/08 is submitted herewith as reference AN.

Identification of the listed reference is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such

reference is available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any listed document should they be applied as a reference against the claims of the subject application.


The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. §1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Applicants respectfully request that the Examiner review the listed reference and that the reference be made of record in the file history of the application.

In accordance with 37 C.F.R. § 1.97(c), since this Supplementary Information Disclosure Statement is being filed after the mailing date of a first Office Action on the merits but before the mailing date of a Notice of Allowance or a Final Office Action, a fee of \$180.00 under 37 C.F.R. § 1.17(p) is believed due in connection herewith. Please charge the required fee, as indicated on the accompanying Fee Transmittal sheet, to Human Genome Science, Inc., Deposit Account No. 08-3425. A copy of this sheet is enclosed.

Respectfully submitted,

Dated: January 21, 2003



Melissa J. Pytel (Reg. No. 41,512)  
Attorney for Applicants

**Human Genome Sciences, Inc.**  
9410 Key West Avenue  
Rockville, MD 20850  
(301) 610-5764 (phone)

MMW/MJP/BM